These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 12879472

  • 21. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G, Cioffi R, De Cataldis G, Maiorino L, Bilancia D, Nicolella G, Natale M, Carpagnano F, Pacilio C, De Lena M, Bianco A, Comella G.
    J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
    [Abstract] [Full Text] [Related]

  • 22. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
    Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Migliorino MR, Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bandera M, Pennucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M, Rosso R.
    Br J Cancer; 1998 Jun; 77(12):2367-70. PubMed ID: 9649160
    [Abstract] [Full Text] [Related]

  • 23. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
    Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, Buzzi F, De Signoribus G, Tuveri G, Rossi G, Di Lullo L, Sturba F, Morale D, Catanzani S, Pilone A, Bonsignori M, Battelli T.
    Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
    [Abstract] [Full Text] [Related]

  • 24. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.
    Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, Efremidis A, Alexopoulos CG, Recloux P, Ninane V, Mommen P, Paesmans M, Klastersky J, European Lung Cancer Working Party.
    Ann Oncol; 2002 Jun; 13(6):874-82. PubMed ID: 12123332
    [Abstract] [Full Text] [Related]

  • 25. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR.
    Clin Cancer Res; 2004 Aug 01; 10(15):5022-6. PubMed ID: 15297403
    [Abstract] [Full Text] [Related]

  • 26. [Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
    Zhang L, Zhang Y, Li N, Xu F, Pan ZK, Guan ZZ.
    Ai Zheng; 2004 Nov 01; 23(11 Suppl):1455-8. PubMed ID: 15566656
    [Abstract] [Full Text] [Related]

  • 27. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
    Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K, Yasumoto K.
    Anticancer Res; 2010 Nov 01; 30(11):4695-9. PubMed ID: 21115926
    [Abstract] [Full Text] [Related]

  • 28. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
    Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ, de las Peñas R, Felip E, López-Vivanco G, Spanish Lung Cancer Group.
    J Clin Oncol; 2003 Sep 01; 21(17):3207-13. PubMed ID: 12947054
    [Abstract] [Full Text] [Related]

  • 29. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C, Franco Conte P.
    Cancer; 2000 Oct 15; 89(8):1714-9. PubMed ID: 11042565
    [Abstract] [Full Text] [Related]

  • 30. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW, Choi EK, Lee JS, Lee SD, Suh C, Kim SW, Kim WS, Ahn SD, Yi BY, Kim JH, Noh YJ, Kim SS, Koh Y, Kim DS, Kim WD.
    Int J Radiat Oncol Biol Phys; 2003 Jul 15; 56(4):996-1004. PubMed ID: 12829135
    [Abstract] [Full Text] [Related]

  • 31. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
    Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M.
    Ann Oncol; 2007 Feb 15; 18(2):317-23. PubMed ID: 17079694
    [Abstract] [Full Text] [Related]

  • 32. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
    Laack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK, German and Swiss Lung Cancer Study Group.
    J Clin Oncol; 2004 Jun 15; 22(12):2348-56. PubMed ID: 15197195
    [Abstract] [Full Text] [Related]

  • 33. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
    Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA.
    Interact Cardiovasc Thorac Surg; 2015 Jun 15; 20(6):783-90. PubMed ID: 25765952
    [Abstract] [Full Text] [Related]

  • 34. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
    Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, de Leede GP, Boezen HM, de Vries EG, Groen HJ.
    Br J Cancer; 2003 Oct 06; 89(7):1192-9. PubMed ID: 14520444
    [Abstract] [Full Text] [Related]

  • 35. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
    Saito H, Nakagawa K, Takeda K, Iwamoto Y, Ando M, Maeda M, Katakami N, Nakano T, Kurata T, Fukuoka M.
    Am J Clin Oncol; 2012 Feb 06; 35(1):58-63. PubMed ID: 21293243
    [Abstract] [Full Text] [Related]

  • 36. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
    Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR.
    Ann Oncol; 1996 Oct 06; 7(8):821-6. PubMed ID: 8922196
    [Abstract] [Full Text] [Related]

  • 37. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
    Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R.
    J Clin Oncol; 1989 Nov 06; 7(11):1602-13. PubMed ID: 2553879
    [Abstract] [Full Text] [Related]

  • 38. Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC).
    Gregory RK, Smith IE, Norton A, Ashley S, O'Brien ME.
    Clin Oncol (R Coll Radiol); 2001 Nov 06; 13(6):483-7. PubMed ID: 11824893
    [Abstract] [Full Text] [Related]

  • 39. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M.
    J Thorac Oncol; 2009 Dec 06; 4(12):1568-71. PubMed ID: 20009911
    [Abstract] [Full Text] [Related]

  • 40. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
    Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K.
    Eur J Cancer; 2017 Sep 06; 83():302-312. PubMed ID: 28780466
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.